HYDROMER INC Form 10OSB February 14, 2005

SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549

FORM 10-QSB

QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended December 31, 2004

Commission File Number 0-10683

HYDROMER, INC.

(Exact name of registrant as specified in its charter) New Jersey 22-2303576

(State of incorporation)

(I.R.S. Employer Identification No.)

35 Industrial Pkwy., Branchburg, New Jersey 08876-3424

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (908) 722-5000

Securities registered pursuant to Section 12 (b) of the Act: None

Securities registered pursuant to Section 12 (g) of the Act:

Common Stock Without Par Value (Title of class)

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such report(s), and (2) has been subject to such filing requirements for the past 90 days. Yes (X)

Indicate the number of shares outstanding or each of the issuer's classes of Common Stock as of the close of the period covered by this report.

> Class Outstanding at December 31, 2004 _____ 4,617,987 Common

> > HYDROMER, INC.

INDEX TO FORM 10-QSB December 31, 2004

Page No.

Part I - Financial Information

C	onsolidated Financial Statements	
В	alance Sheets - December 31, 2004 & June 30, 2004	2
-	tatements of Income for the three months and six months ended December 31, 2004 and 2003	3
	tatements of Cash Flows for the six months ended December 31, 2004 and 2003	4
N	otes to Financial Statements	5
	Management's Discussion and Analysis of the Financial Condition and Results of Operations	6
Part II - O	ther Information	8
	EXHIBIT INDEX	

Exhibit No.	Description of Exhibit	
33.1	SEC Section 302 Certification - CEO certification	10
33.2	SEC Section 302 Certification - CFO certification	11
99.1	Certification of Manfred F. Dyck, Chief Executive Officer, pursuant to 18 U.S.C. Section 1350	12
99.2	Certification of Robert Y. Lee, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350	12

-1-

HYDROMER, INC. and CONSOLIDATED SUBSIDIARY CONSOLIDATED BALANCE SHEETS

	Dec	cember 31, 2004	June 30, 2004
	UU	NAUDITED	AUDITED
Assets			
Current Assets:			
Cash and cash equivalents	\$	253,224	\$ 142,476
Trade receivables less allowance for			
doubtful accounts of \$31,497 as of			
December 31, 2004 and \$10,727 as of			
June 30, 2004		1,852,776	1,715,309
Inventory		893 , 925	808,989
Prepaid expenses		86 , 780	124,799
Deferred tax asset		160,101	141,798
Other		32,681	32,638
Total Current Assets	-	3,279,487	2,966,009

Property and equipment, net	3,115,692	2,921,560
Intangible assets, net	767,715 238,172	676,291 238,172
Total Assets	\$ 7,401,066	\$ 6,802,032
Liabilities and Stockholders' Equity Current Liabilities: Accounts payable	\$ 563,461 652,639 302,327 - 158,500 92,937 40,110 1,809,974 203,222 173,500	\$ 524,917 131,010 246,019 187,635 26,000 91,507 88,317
Long-term portion of mortgage payable Total Liabilities	1,317,562 3,504,258	1,363,723 2,954,628
Stockholders' Equity	3,504,258	2,954,628
Preferred stock - no par value, authorized 1,000,000 shares, no shares issued and outstanding Common stock - no par value, authorized 15,000,000 shares; as of December 31, 2004, 4,628,904 shares issued and 4,617,987 shares outstanding; as of June 30, 2004, 4,608,904 shares issued	-	-
and 4,597,987 shares outstanding Contributed capital Accumulated deficit Treasury stock, 10,917 common shares at cost	3,631,615 577,750 (306,417) (6,140)	3,615,615 577,750 (339,821) (6,140)
Total Stockholders' Equity	3,896,808	3,847,404
Total Liabilities and Stockholders' Equity	\$ 7,401,066	\$ 6,802,032

-2-

HYDROMER, INC. and CONSOLIDATED SUBSIDIARY CONSOLIDATED STATEMENTS OF INCOME

		ths Ended ber 31, 2003		ths Ended aber 31, 2003
	UNA	UDITED	UNAU	JDITED
Revenues				
Sale of products	\$1,202,592	\$1,236,708	\$2,273,755	\$2,211,959
Service revenues	303,683	154 , 568	585 , 312	261,209

licenses	675,421	590,410	1,268,959	1,148,383
Total Revenues	2,181,696		4,128,026	3,621,551
Expenses				
Cost of Sales	757,406	755 , 670	1,456,163	1,343,485
Operating Expenses	1,302,102	1,061,255	2,579,886	2,072,925
Other Expenses	25,780	31,214	47,560	61 , 952
Provision for Income Taxes	39 , 618	53 , 404	11,012	53 , 663
Total Expenses	2,124,906	1,901,543	4,094,621	3,532,025
Net Income	\$ 56,790 ======	\$ 80,143 ======	\$ 33,405 =====	•
Earnings Per Common Share	\$ 0.01	·	\$ 0.01	
Weighted Average Number of Common Shares Outstanding	4,613,150	4,597,063	4,605,569	4,592,525

The effects of the common stock equivalents on diluted earnings per share are not included as they have no impact.

-3-

HYDROMER, INC. and CONSOLIDATED SUBSIDIARY CONSOLIDATED STATEMENTS OF CASH FLOWS

	Six Months Ended December 31, 2004 2003		
	UNAUDITED		
Cash Flows From Operating Activities: Net Income	\$ 33,405	\$ 89,526	
Depreciation and amortization	97,452	90,244	
Deferred income taxes	(6,581)	(4,000)	
Trade receivables	(137,467)	(167 , 305)	
Inventory	(84,936)	(39,418)	
Prepaid expenses	38,019	16,201	
Patents and Trademark	(91,424)	(36, 372)	
Other assets	(43)		
liabilities	109,216	156 , 692	
Income taxes payable	(48,207)	37,133	
Net Cash (Used for) Provided by			
Operating Activities	(90 , 566)	155 , 964	
Cash Flows From Investing Activities: Cash purchases of property and equipment	(291.584)	(118,925)	
cquipment	(231,301)	(110, 323)	

Net Cash Used for Investing		
Activities	(291,584)	(118,925)
Cash Flows From Financing Activities: Net borrowings against Line of		
Credit	521,629	56,683
Repayment of long-term borrowings	(44,731)	(597,774)
Proceeds from long-term borrowings Proceeds from the issuance of common	_	555,000
stock	16,000	7,497
Net Cash Provided by Financing		
Activities	492,898	21,406
Net Increase in Cash and Cash Equivalents:	110,748	58,445
Cash and Cash Equivalents at Beginning of Period	142,476	97,676
Cash and Cash Equivalents at End of		
Period	\$ 253,224	\$ 156,121
	======	======

-4-

HYDROMER, INC. and CONSOLIDATED SUBSIDIARY Notes to Consolidated Financial Statements

In the opinion of management, the accompanying unaudited financial statements include all adjustments (consisting of only normal adjustments) necessary for a fair presentation of the results for the interim periods. Certain reclassifications have been made to the previous year's results to present comparable financial statements.

Segment Reporting:

The Company operates two primary business segments. The Company evaluates the segments by revenues, total expenses and earnings before taxes. Corporate Overhead is excluded from the business segments as to not distort the contribution of each segment.

The results for the six months ended December 31, by segment are:

	Polymer Research	Medical Products	Corporate Overhead	Total
2004				
Revenues	\$ 2,631,063	\$ 1,496,963	_	\$ 4,128,026
Expenses	(1,762,884)	(1,683,097)	\$ (637,628)	(4,083,609)
Earnings (Loss) before				
Income Taxes	\$ 868,179	\$ (186,134)	\$ (637,628)	\$ 44,417
	=======	=======	======	=======
2003				
Revenues	\$ 2,245,559	\$ 1,375,992	_	\$3,621,551
Expenses	(1,456,255)	(1,451,412)	(570,695)	(3,478,362)

Earnings (Loss) before

Income Taxes...... \$ 789,304 \$ (75,420) \$ (570,695) \$ 143,189

The prior period segment information has been restated to conform to the current year presentation.

Geographic revenues were as follows for the six months ended December 31,

	2004	2003
Domestic	82%	82%
Foreign	18%	18%

-5-

MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Results of Operations

The Company's revenues for the quarter ended December 31, 2004 were \$2,181,696 as compared to \$1,981,686 for the same period last year or a 10.1% increase. Revenues for the six months ended December 31, 2004 were \$4,128,026, up 14.0% from \$3,621,551 the corresponding period a year ago. Revenues are comprised of the sale of Products and Services and Royalty, Options and License payments.

Product sales and services were \$1,506,275 for the quarter ended December 31, 2004 as compared to \$1,391,276 for the same period last year, an increase of 8.3%. For the six months ended December 31, 2004, product sales and services were \$2,859,067 as compared to \$2,473,168 the prior year, a 15.6% increase. Stronger sales in our contract coating, R&D Services and Cosmetic product lines this year contributed to the increase.

Royalty, license and option revenues from patented products were \$675,421 for the quarter, up 14.4% from \$590,410 the same period a year ago. For the six months ended December 31, 2004, royalty, license and option revenues were \$1,268,959, up 10.5% from \$1,148,383 the same period a year ago.

As of December 31, 2004, our open sales order book was approximately \$982,000, which represents orders for delivery during the remainder of the current fiscal year. Some of these orders are subject to cancellation, however, the Company is of the opinion that no substantial cancellations will occur. Our open order book excludes though, future orders that would come up during the normal course of business for immediate delivery also during this fiscal year.

Total Expenses for the quarter ended December 31, 2004 were \$2,124,906 as compared with \$1,901,543 the year before, or an increase of 11.7%. For the six months ended December 31, 2004, total Expenses were \$4,094,621 as compared with \$3,532,025 the same period the year before, an increase of 15.9%

The Company's Cost of Goods Sold was \$757,406 for the quarter ended December 31, 2004 as compared with \$755,670 the year prior, an increase of 0.2%. On a year-to-date basis, cost of goods sold was \$1,456,163 this year as compared with \$1,343,485 the corresponding

period a year ago, an increase of 8.4%. There was a higher cost of goods sold corresponding to the increase in products and services revenues.

Operating expenses were \$1,302,102 for the quarter ended December 31, 2004 as compared with \$1,061,255 the year before, an increase of \$240,847 or 22.7%. For the six month periods, operating expenses were \$2,579,886 this year as compared with \$2,072,925 the previous year. The addition of four scientists, a production manager and a QC manager since March 1, 2004, as part of the Company's investment for the future, resulted in an increase of \$192,000 in higher personnel costs. In addition, during this six month period, the Company expended an additional \$80,000 in litigation costs in its continued infringement claim against a former licensee and other parties.

Interest expense for the six months ended December 31, 2004 and December 31, 2003 were \$50,934 and \$63,745, respectively, lower this period as a result of the lower interest rates: from the refinance of the first mortgage in October 2003 and from the amortization of the mortgage balances.

-6-

Income before Income Taxes was \$96,408 for the current quarter as compared with \$133,547 the same period a year before. For the six months ended December 31, 2004, Income before Income Taxes was \$44,417 compared with \$143,189 a year ago.

Net Income of \$56,790 (\$0.01 per share) is reported for the quarter ended December 31, 2004 as compared to Net Income of \$80,143 (\$0.02 per share) the year before. For the six months ended December 31, 2004, Net Income of \$33,405 (\$0.01 per share) is reported as compared to Net Income of \$89,526 (\$0.02 per share) the year before.

Our reinvestment back into the Company (primarily from an increase in R&D staffing) increased current operating expenses for planned returns in the future.

Financial Condition

Working capital decreased \$201,090 during the six months ended December 31, 2004. Management believes that its current working capital and available line of credit, along with expected income and expense streams, are sufficient to maintain its current level of operations.

Operating activities used \$90,566 for the six month period ended December 31, 2004.

The Net income adjusted for non-cash expenses, provided \$124,276 in net cash. Working capital accounts utilized \$214,842 in net cash: primarily due to the increase in accounts receivables \$137,467 and \$91,424 for patent expenses.

Investing activities used \$291,584 on capital expenditures and financing activities provided \$492,898 during the six months ended December 31, 2004.

Capital expenditures (the adding of new production capabilities and facilities to meet current demand as well as expanding our QA laboratories and general building maintenance & improvements) were the Company's investing activities this period.

The Company manages its working capital and other cash requirements through utilization of its available short-term borrowings - a revolving Line of Credit. During the six months ending December 31, 2004, the Company borrowed, net of repayments, \$521,629 from the Line-of-Credit.

Due to the Company's self-funding of capital expenditures, which was un-typically high, the Company did not meet a ratio coverage covenant on its mortgage loan. During the past twelve months the Company has added new facilities and equipment in the areas of production, research and development and Quality Assurance as well as repaired its roof and replaced HVAC equipment. The Company is near completion of this initiative which will be sufficient for the existing and near future level of operations and R&D initiatives.

The Company's ability to repay the loan under the normal terms of the loan is unhindered and they believe that this issue can be resolved at no or minimal costs.

-7-

Disclosure Controls and Procedures

The evaluation of the Company's Internal Controls Environment concluded that it was effective for the safeguarding of assets and in ensuring that management is presented material information regarding the organization. The evaluation also determined that there are areas that could be improved upon, however, the controls and procedures in place were appropriate for the type and size of the Company.

The Company has again reviewed its Internal Controls Environment during the prior 90 days, and it has been determined that there have been no significant changes in internal controls or in other factors that could significantly affect the financial statements.

Litigation:

In May of 2004 the Company filed a suit in the District Court of New Jersey against a former licensee of its T-Hexx products and against an agricultural distributor selling certain products in the west and mid-west. The suit alleges among other things, that the defendants infringed on various patents belonging to the Company and illegally used Company trademarks. The former licensee denied the allegations. The disbributor denied the allegations and filed counterclaims against the Company alleging inequitable conduct in obtaining and enforcing the patents and various anti-trust activities. The matter has just begun discovery but the Company is of the opinion that such counterclaims are totally wihout merit.

PART II - Other Information

The Company operates entirely from its sole location at 35 Industrial Parkway in Branchburg, New Jersey, an owned facility secured by mortgages through banks.

The existing facility will be adequate for the Company's operations for the foreseeable future.

Item 6. Exhibits and Reports on Form 8-K:

- a) Exhibits none
- b) Reports on Form 8-K Two Form 8-K's were filed during the quarter ending December 31, 2004. One reported the Company's announcement of earnings for the first quarter ending September 30, 2004. The second Form 8-K reported the Company's announcement of receiving a research grant from the National Institute of Health.

-8-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on his behalf by the undersigned thereunto duly authorized.

HYDROMER, INC.

/s/ Robert Y. Lee
-----Robert Y. Lee

Chief Financial Officer

DATE: February 11, 2005

-9-